David A. Siegel Stealth Bio Therapeutics Corp Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.2 - $0.32 $340 - $544	-1,700 Reduced 11.04%	13,700 $4,000
Q2 2022 Aug 15, 2022	SELL	$0.18 - $0.71 $180 - $710	-1,000 Reduced 6.1%	15,400 $4,000
Q1 2022 May 16, 2022	SELL	$0.49 - $0.9 $4,312 - $7,920	-8,800 Reduced 34.92%	16,400 $11,000
Q4 2021 Feb 14, 2022	SELL	$0.76 - $1.48 $152 - $296	-200 Reduced 0.79%	25,200 $21,000
Q3 2021 Nov 15, 2021	BUY	$1.17 - $1.58 $3,159 - $4,266	2,700 Added 11.89%	25,400 $35,000
Q2 2021 Aug 16, 2021	BUY	$1.07 - $1.77 $24,289 - $40,179	22,700 New	22,700 $35,000

2.94K

Ticker MITO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,548,600
Description
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duche...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.